Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Summary

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Non-Small Cell Lung Cancer, NSCLC
• KRAS, NRAS, HRAS-mutated NSCLC
• KRAS G12C-mutated Solid Tumors, Lung Cancer
• Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
• RAS G12D-mutated NSCLC

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1/2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Revolution Medicines, Inc.

Last updated on ClinicalTrials.gov

June 30, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites